Utilizing artificial intelligence along with traditional pathology offers promise for swiftly developing treatment plans for patients with non-small cell lung cancers, a team led by UT Southwestern Medical Center researchers discovered.
Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
